Rebecca Araujo

Urban Health Today

The novel chimeric antigen receptor (CAR) T cell therapy, CT053, achieved a 100% overall response rate (ORR) for the treatment of relapsed/refractory <a href="https://www.docwirenews.com/condition-center/multiple-myeloma-knowledge-hub/recent-fda-approvals-for-multiple-myeloma-and-what-to-expect-from-treatments-in-development/" target="_blank" rel="noopener noreferrer">multiple myeloma</a> (RRMM), though toxicity was common, according to data presented at the American Society of Hematology 2020 virtual annual conference (<a href="https://ash.confex.com/ash/2020/webprogram/Paper139802.html">abstract #133</a>).CT053 is a second-generation CAR T that incorporates a fully human <a href="https://www.docwirenews.com/condition-center/multiple-myeloma-knowledge-hub/multiple-myeloma-picks/bcma-cd30-bispecific-antibody-induces-response-in-relapsed-refractory-multiple-myeloma/" target="_blank" rel="noopener noreferrer">B-cell maturation antigen</a> (BCMA)-specific single-chain fragment variant. In a phase I study, CT053 induced responses in 87.5% of patients with RRMM, including 79.2% achieving a complete response (CR), for a median duration of 21.8 months.The phase Ib LUMMICAR-2 study enrolled 20 patients with RRMM whose disease persisted after &ge;3 prior lines of therapy. Participants received 500 mg/m2 cyclophosphamide for two days and 25 mg/m2 fludarabine daily three days. Following lymphodepletion, a single infusion of CT053 was administered at the 1.5-3.0&times;108 CAR+ T-cell target dose. At data cutoff, 14 patients received infusion and 10 were evaluated after a median 4.5 months. Primary endpoints were safety and tolerability, and identification of recommended dosing for phase II.An ORR of 100% was achieved, with two stringent CRs, two CRs, one very good partial response, and five partial responses. Eleven of twelve patients with evaluable bone marrow samples were minimal-residual disease (MRD)-negative. All subjects showed declines in serum free light chains and soluble BCMA (sBCMA) levels at one month, with continued sBCMA depletion. Cytokine levels increased post-infusion and correlated with the onset of cytokine release syndrome (CRS) symptoms.Toxicity was common, with twelve subjects (86%) experiencing grade 1 or 2 CRS, and one subject experiencing grade 2 neurotoxicity. CRS events occurred a median two days post-infusion with a median duration of four days. No &ge; grade 3 CRS or neurotoxicity was observed. All subjects experienced &ge; grade 3 neutropenia and leukopenia, and 36% had &ge; grade 3 thrombocytopenia.&ldquo;Collectively, these results demonstrate that CT053 at a target dose of 1.5-3.0&times;108 CAR+ T cells delivers early and deep responses, including MRD negativity, with an acceptable safety profile in subjects with heavily pretreated relapsed or refractory MM. The promising results from the ongoing LUMMICAR-2 study are consistent with the previous phase I studies and support the launch of a pivotal phase II LUMMICAR-2 study,&rdquo; the researchers concluded.<blockquote class="twitter-tweet">
Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma 
&ndash; What is CT053 
&ndash; Trial Design 
&ndash; Inclusion criteria <a href="https://twitter.com/myelomaMD?ref_src=twsrc%5Etfw">@myelomaMD</a> <a href="https://twitter.com/hashtag/ASH20?src=hash&amp;ref_src=twsrc%5Etfw">#ASH20</a> <a href="https://twitter.com/hashtag/IMFASH20?src=hash&amp;ref_src=twsrc%5Etfw">#IMFASH20</a> <a href="https://twitter.com/hashtag/MMSM?src=hash&amp;ref_src=twsrc%5Etfw">#MMSM</a> <a href="https://t.co/HIxafnQAJJ">pic.twitter.com/HIxafnQAJJ</a>
&mdash; =NorthTX Yelak= (@NorthTxMSG) <a href="https://twitter.com/NorthTxMSG/status/1335294851726925825?ref_src=twsrc%5Etfw">December 5, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet">
Report on LUMMICAR2 from <a href="https://twitter.com/myelomaMD?ref_src=twsrc%5Etfw">@myelomaMD</a> with CT053, fully humanized BCMA CAR T, Ph1b/2 in 20 pts. No grade 3 or higher CRS, 94% ORR <a href="https://t.co/tXgS7UOkY5">pic.twitter.com/tXgS7UOkY5</a>
&mdash; Multiple Myeloma RF (@theMMRF) <a href="https://twitter.com/theMMRF/status/1335304205964353543?ref_src=twsrc%5Etfw">December 5, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

Lou Portero

Climate Change Is Loading Rice With Arsenic

Public Health

FDA Authorizes First Prescription Digital Therapeutic for Migraine Prevention

Women's Neurology

How Vagus Nerve Signals Affect Eating Habits Across Socioeconomic Lines

Obesity

Latest News

LUMMICAR-2: CT053 BCMA CAR T Is Active in Refractory Myeloma, But Toxicity Persists

Multiple Myeloma

The novel chimeric antigen receptor (CAR) T cell therapy, CT053, achieved a 100% overall response rate (ORR) for the ...